American Century Companies Inc. Sells 47,750 Shares of Exelixis, Inc. (NASDAQ:EXEL)

American Century Companies Inc. reduced its holdings in shares of Exelixis, Inc. (NASDAQ:EXEL - Free Report) by 10.3% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 415,865 shares of the biotechnology company's stock after selling 47,750 shares during the quarter. American Century Companies Inc. owned approximately 0.15% of Exelixis worth $13,848,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Cerity Partners LLC grew its position in shares of Exelixis by 129.1% during the 3rd quarter. Cerity Partners LLC now owns 27,994 shares of the biotechnology company's stock worth $726,000 after purchasing an additional 15,777 shares in the last quarter. Bank of Montreal Can raised its holdings in Exelixis by 51.5% in the 3rd quarter. Bank of Montreal Can now owns 104,385 shares of the biotechnology company's stock valued at $2,710,000 after buying an additional 35,496 shares during the last quarter. FMR LLC lifted its holdings in shares of Exelixis by 6.1% during the third quarter. FMR LLC now owns 2,462,072 shares of the biotechnology company's stock worth $63,891,000 after purchasing an additional 140,568 shares during the period. Quantbot Technologies LP bought a new position in Exelixis during the 3rd quarter worth $149,000. Finally, CreativeOne Wealth LLC bought a new position in shares of Exelixis during the third quarter worth about $203,000. 85.27% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other Exelixis news, CFO Christopher J. Senner sold 29,314 shares of the firm's stock in a transaction that occurred on Monday, February 24th. The stock was sold at an average price of $36.14, for a total value of $1,059,407.96. Following the completion of the sale, the chief financial officer now owns 779,607 shares in the company, valued at approximately $28,174,996.98. This trade represents a 3.62 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Patrick J. Haley sold 52,636 shares of the firm's stock in a transaction that occurred on Monday, February 24th. The stock was sold at an average price of $36.98, for a total transaction of $1,946,479.28. Following the sale, the executive vice president now directly owns 303,310 shares of the company's stock, valued at approximately $11,216,403.80. The trade was a 14.79 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 140,343 shares of company stock valued at $5,177,234 over the last 90 days. 2.85% of the stock is currently owned by company insiders.

Remove Ads

Analyst Ratings Changes

EXEL has been the subject of a number of analyst reports. HC Wainwright reiterated a "buy" rating and set a $40.00 price objective on shares of Exelixis in a report on Thursday, March 27th. Piper Sandler lifted their price target on Exelixis from $37.00 to $38.00 and gave the company an "overweight" rating in a research report on Wednesday, February 12th. Brookline Capital Management began coverage on shares of Exelixis in a research note on Monday, December 23rd. They issued a "buy" rating on the stock. Stephens restated an "equal weight" rating and set a $29.00 price objective on shares of Exelixis in a research report on Wednesday, February 12th. Finally, Guggenheim reaffirmed a "buy" rating and issued a $42.00 target price on shares of Exelixis in a research note on Wednesday, February 12th. One analyst has rated the stock with a sell rating, eight have issued a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average price target of $37.59.

Exelixis Stock Performance

NASDAQ:EXEL traded down $2.11 during trading hours on Friday, hitting $34.57. The company's stock had a trading volume of 2,944,993 shares, compared to its average volume of 2,149,678. The company has a market capitalization of $9.68 billion, a PE ratio of 19.53, a PEG ratio of 1.13 and a beta of 0.57. Exelixis, Inc. has a 52-week low of $20.14 and a 52-week high of $40.02. The business's 50-day moving average is $35.90 and its two-hundred day moving average is $33.65.

Exelixis (NASDAQ:EXEL - Get Free Report) last released its quarterly earnings data on Tuesday, February 11th. The biotechnology company reported $0.48 EPS for the quarter, missing the consensus estimate of $0.51 by ($0.03). Exelixis had a net margin of 24.04% and a return on equity of 23.52%. As a group, analysts predict that Exelixis, Inc. will post 2.04 EPS for the current fiscal year.

Exelixis Company Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.